Last10K.com

21St Century Oncology Holdings, Inc. (RTSX) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2015

21St Century Oncology Holdings, Inc.

HISTORY TOOLS
CIK: 1503518 Ticker: RTSX

Exhibit 99.1

 

 

21ST CENTURY ONCOLOGY HOLDINGS, INC.

 

21st Century Oncology Contact:

Investor Contact:

LeAnne M. Stewart

The Ruth Group

Chief Financial Officer

Nick Laudico

239-931-7281

646-536-7030

leanne.stewart@21co.com

nlaudico@theruthgroup.com

 

 

 

Brandon Vazquez

 

646-536-7032

 

bvazquez@theruthgroup.com

 

21ST CENTURY ONCOLOGY HOLDINGS INC. REPORTS FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS

 

COMPLETES FINANCIAL RESTATEMENT

 

FORT MYERS, FL, August XX, 2016 — 21

st Century Oncology Holdings, Inc. (“21C” or the “Company”), the leading global, physician-led provider of integrated cancer care services, announced today its financial results for the fourth quarter and full year ended December 31, 2015 and announced the completion of the restatement of financial results for the years ended December 31, 2012, 2013 and 2014, the unaudited condensed consolidated financial statements as of and for each of the interim periods within the years ended December 31, 2012, 2013 and 2014 and for the interim periods ended March 31, June 30, and September 30, 2015.

 

Fourth Quarter 2015 and Full Year 2015 Results

 

Total revenues for the fourth quarter of 2015 were $263.1 million, down 1.3% as compared to total revenues of $266.6 million in the same quarter of 2014. Revenue growth from acquired and new operations was offset by approximately $3.3 million relative to the effect of simulation code bundling. Net income for the fourth quarter was $7.0 million versus a net loss of $28.3 million for the same period in the prior year. The improvement in net income resulted from a fair market value adjustment for embedded derivatives.

 

Pro-forma adjusted EBITDA in the fourth quarter of 2015 was $38.8 million, or 14.7% of total pro-forma revenues, as compared to $30.7 million, or 11.5% of total pro-forma revenues, in the fourth quarter of 2014. The primary contributor to the pro-forma adjusted EBITDA improvement was a $6.2 million reduction in compensation expense and $5.1 million improvement in bad debt offset by the $3.5 million decrease in total revenues.

 

Total radiation oncology treatments per day during the fourth quarter increased 1.8% over the same period in the prior year and same market radiation oncology treatments per day for the quarter declined 2.0% compared to the same period in the prior year. As previously disclosed,

 

The following information was filed by 21St Century Oncology Holdings, Inc. (RTSX) on Tuesday, August 23, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate 21St Century Oncology Holdings, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by 21St Century Oncology Holdings, Inc..

Continue

Assess how 21St Century Oncology Holdings, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

21St Century Oncology Holdings, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Cash Flows (parenthetical)
Consolidated Statements Of Changes In Equity (deficit)
Consolidated Statements Of Operations And Comprehensive Loss
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Acquisitions And Other Arrangements
Acquisitions And Other Arrangements (narrative) (details)
Acquisitions And Other Arrangements (schedule Of Estimated Future Amortization Expense For The Acquired Amortizable Intangible Assets) (details)
Acquisitions And Other Arrangements (schedule Of The Allocation Of The Purchase Price) (details)
Acquisitions And Other Arrangements (schedule Of Unaudited Pro Forma Financial Information) (details)
Acquisitions And Other Arrangements (summary Of Allocation Of The Aggregate Purchase Price, Including Assumed Liabilities) (details)
Acquisitions And Other Arrangements (tables)
Capital Lease Arrangements
Capital Lease Arrangements (details)
Capital Lease Arrangements (tables)
Commitments And Contingencies
Commitments And Contingencies (future Minimum Annual Lease Commitments) (details)
Commitments And Contingencies (narrative) (details)
Commitments And Contingencies (schedule Professional Liability Claims And Recoveries) (details)
Commitments And Contingencies (tables)
Convertible Redeemable Preferred Stock
Convertible Redeemable Preferred Stock (narrative) (details)
Convertible Redeemable Preferred Stock (schedule Of Changes To Series A Preferred Stock) (details)
Convertible Redeemable Preferred Stock (tables)
Equity Investments In Joint Ventures
Equity Investments In Joint Ventures (narrative) (details)
Equity Investments In Joint Ventures (schedule Of The Condensed Financial Position) (details)
Equity Investments In Joint Ventures (schedule Of The Condensed Results Of Operations) (details)
Equity Investments In Joint Ventures (summary Of The Changes In The Equity Investment In Joint Ventures) (details)
Equity Investments In Joint Ventures (tables)
Fair Value Of Financial Instruments
Fair Value Of Financial Instruments (narrative) (details)
Fair Value Of Financial Instruments (schedule Of Changes In Level 3 Liabilities) (details)
Fair Value Of Financial Instruments (schedule Of Fair Value Debt Instruments Based On Level 2) (details)
Fair Value Of Financial Instruments (schedule Of Items Measured At Fair Value On Recurring Basis) (details)
Fair Value Of Financial Instruments (tables)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (narrative) (details)
Goodwill And Intangible Assets (schedule Of Changes In The Carrying Amount Of Goodwill) (details)
Goodwill And Intangible Assets (schedule Of Components Of Intangible Assets) (details)
Goodwill And Intangible Assets (schedule Of Estimated Future Amortization Expense) (details)
Goodwill And Intangible Assets (tables)
Income Taxes
Income Taxes (narrative) (details)
Income Taxes (reconciliation Of Statutory Tax Rate To Effective Tax Rate) (details)
Income Taxes (schedule Of Deferred Tax Assets And Liabilities) (details)
Income Taxes (schedule Of Reconciliation Of Gross Unrecognized Tax Benefits) (details)
Income Taxes (schedule Of Significant Components Of Income Tax Provision) (details)
Income Taxes (schedule Of Valuation Allowance) (details)
Income Taxes (tables)
Liquidity
Liquidity (details)
Long-term Debt
Long-term Debt (deferred Financing Costs) (narrative) (details)
Long-term Debt (mdllc Credit And Guaranty Agreement) (narrative) (details)
Long-term Debt (purchase Money Note Purchase Agreement) (narrative) (details)
Long-term Debt (schedule Of Company's Long-term Debt) (details)
Long-term Debt (schedule Of Financial Covenants Compliance Under The Revolving Credit Facility) (details)
Long-term Debt (schedule Of Maturities Of Long-term Debt Obligations) (details)
Long-term Debt (senior Notes) (narrative) (details)
Long-term Debt (senior Secured Credit Facility) (narrative) (details)
Long-term Debt (senior Secured Notes) (narrative) (details)
Long-term Debt (senior Secured Second Lien Notes) (narrative) (details)
Long-term Debt (senior Subordinated Notes) (narrative) (details)
Long-term Debt (sfro Pik Notes) (narrative) (details)
Long-term Debt (tables)
Long-term Debt (term Facility) (narrative) (details)
Long-term Debt (term Loan A And B Facilities) (narrative) (details)
Marketable Securities
Marketable Securities (details)
Organization And Basis Of Presentation
Organization And Basis Of Presentation (details)
Other Income And Loss
Other Income And Loss (narrative) (details)
Property And Equipment
Property And Equipment (details)
Property And Equipment (tables)
Real Estate Subject To Finance Obligation
Real Estate Subject To Finance Obligation (narrative) (details)
Real Estate Subject To Finance Obligation (schedule Of Future Payments Of The Finance Obligation) (details)
Real Estate Subject To Finance Obligation (schedule Of Net Book Values Of Real Estate Subject To Finance Obligation) (details)
Real Estate Subject To Finance Obligation (tables)
Reconciliation Of Total Equity And Noncontrolling Interests
Reconciliation Of Total Equity And Noncontrolling Interests (details)
Reconciliation Of Total Equity And Noncontrolling Interests (tables)
Related-party Transactions
Related-party Transactions (details)
Restatement Of Consolidated Financial Statements
Restatement Of Consolidated Financial Statements (summary Of Effects Of Restatement Adjustments On Accumulated Deficit Balance) (details)
Restatement Of Consolidated Financial Statements (summary Of Effects Of Restatement Adjustments On Consolidated Financial Statements - Balance Sheets) (details)
Restatement Of Consolidated Financial Statements (summary Of Effects Of Restatement Adjustments On Consolidated Financial Statements - Cash Flows) (details)
Restatement Of Consolidated Financial Statements (summary Of Effects Of Restatement Adjustments On Consolidated Financial Statements - Operations And Comprehensive Loss) (details)
Restatement Of Consolidated Financial Statements (tables)
Retirement And Deferred Compensation Plans
Retirement And Deferred Compensation Plans (assumptions Used To Determine Net Periodic Pension Benefit Cost) (details)
Retirement And Deferred Compensation Plans (changes In Projected Benefit Obligation And Fair Value Of Plan Assets) (details)
Retirement And Deferred Compensation Plans (fair Value Of Total Plan Assets By Major Asset Category) (details)
Retirement And Deferred Compensation Plans (investments And Obligations Of The Coli Plan) (details)
Retirement And Deferred Compensation Plans (narrative) (details)
Retirement And Deferred Compensation Plans (schedule Of Amounts Recognized In Other Comprehensive Income (loss)) (details)
Retirement And Deferred Compensation Plans (schedule Of Expected Benefit Payments) (details)
Retirement And Deferred Compensation Plans (schedule Of Net Benefit Costs) (details)
Retirement And Deferred Compensation Plans (tables)
Segment And Geographic Information
Segment And Geographic Information (narrative) (details)
Segment And Geographic Information (schedule Of Financial Information By Geographic Segment) (details)
Segment And Geographic Information (schedule Of Reconciliation Of The Company's Reportable Segment Profit And Loss) (details)
Segment And Geographic Information (tables)
Stock Option Plan And Restricted Stock Grants
Stock Option Plan And Restricted Stock Grants (narrative) (details)
Stock Option Plan And Restricted Stock Grants (summary Of Units Activity Under The Plan) (details)
Stock Option Plan And Restricted Stock Grants (summary Of Units To Be Forfeited Upon Certain Events) (details)
Stock Option Plan And Restricted Stock Grants (tables)
Subsequent Events
Subsequent Events (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (narrative) (details)
Summary Of Significant Accounting Policies (policy)
Summary Of Significant Accounting Policies (schedule Of Components Of Accumulated Other Comprehensive Loss) (details)
Summary Of Significant Accounting Policies (schedule Of Inventories) (details)
Summary Of Significant Accounting Policies (schedule Of Major Asset Classifications And Useful Lives) (details)
Summary Of Significant Accounting Policies (summary Of The Activity In The Allowance For Doubtful Accounts) (details)
Summary Of Significant Accounting Policies (tables)
Unaudited Quarterly Financial Information
Unaudited Quarterly Financial Information (narrative) (details)
Unaudited Quarterly Financial Information (schedule Of Unaudited Quarterly Interim Financial Information) (balance Sheet) (details)
Unaudited Quarterly Financial Information (schedule Of Unaudited Quarterly Interim Financial Information) (cash Flows) (details)
Unaudited Quarterly Financial Information (schedule Of Unaudited Quarterly Interim Financial Information) (details)
Unaudited Quarterly Financial Information (schedule Of Unaudited Quarterly Interim Financial Information) (statements Of Operations And Comprehensive Loss) (details)
Unaudited Quarterly Financial Information (tables)
Ticker: RTSX
CIK: 1503518
Form Type: 10-K Annual Report
Accession Number: 0001047469-16-015101
Submitted to the SEC: Tue Aug 23 2016 4:58:38 PM EST
Accepted by the SEC: Tue Aug 23 2016
Period: Thursday, December 31, 2015
Industry: Offices And Clinics Of Doctors Of Medicine

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/rtsx/0001047469-16-015101.htm